Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia

Journal of Immunology

Volumn 168, Issue 8, 2002, Pages 4070-4077

  Branger, Judith ^a   Van Den Blink, Bernt ^a   Weijer, Sebastiaan ^a   Madwed, Jeffrey ^a   Bos, Carina L ^a   Gupta, Abhya ^a   Yong, Chan Loi ^a   Polmar, Stephen H ^a   Olszyna, Dariusz P ^a   Hack, C Erik ^a   Van Deventer, Sander J H ^a   Peppelenbosch, Maikel P ^a   Van der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIRB 796 BS; C REACTIVE PROTEIN; CD11B ANTIGEN; ELASTASE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; L SELECTIN; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; SYNAPTOPHYSIN; TRYPSIN INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DOWN REGULATION; ENDOTOXEMIA; ENZYME ACTIVATION; ENZYME RELEASE; HUMAN; HUMAN CELL; INFLAMMATION; LEUKOCYTE; NEUTROPHILIA; NORMAL HUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

EID: 0037090078     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.168.8.4070     Document Type: Article

References (46)

1. Protein kinases and phosphatases: The yin and yang of protein phosphorylation and signaling
2. Sounding the alarm: Protein kinase cascades activated by stress and inflammation
3. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells
4. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis
5. The stress-activated protein kinase subfamily of c-Jun kinases
6. p38 MAPK signalling cascades in inflammatory disease
7. The p38 signal transduction pathway: Activation and function
8. Inhibition of p38 MAP kinase as a therapeutic strategy
9. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function
10. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence
11. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis
12. p38 mitogen-activated protein kinase inhibition increases cytokine release by macrophages in vitro and during infection in vivo
13. Role of p38 mitogen-activated protein kinase in a murine model of pulmonary inflammation
14. Evolution of an immune suppressive macrophage phenotype as a product of P38 MAPK activation in polymicrobial sepsis
15. Endotoxemia in healthy subjects as a human model of inflammation
16. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site
17. 1-antitrypsin and lactoferrin in sepsis: Evidence for neutrophils as mediators in fatal sepsis
18. Extracellular signal-regulated kinase and p38 subgroups of mitogen-activated protein kinases regulate inducible nitric oxide synthase and tumor necrosis factor-α gene expression in endotoxin-stimulated primary glial cultures
19. Selective activation and functional significance of p38α mitogen-activated protein kinase in lipopolysaccharide-stimulated neutrophils
20. Neutrophil Mac-1 and MEL-14 adhesion proteins inversely regulated by chemotactic factors
21. An intracellular signaling pathway linking lipopolysaccharide stimulation to cellular responses of the human neutrophil: The p38 MAP kinase cascade and its functional significance
22. Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-α: Role of the p38 and p42/44 mitogen-activated protein kinases
23. MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis
24. Lipopolysaccharide-induced tumor necrosis factor α production by human monocytes involves the raf-1/MEK1-MEK2/ERK1-ERK2 pathway
25. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase
26. Activation of c-Jun N-terminal kinase in bacterial lipopolysaccharide-stimulated macrophages
27. Regulation of TNF expression by multiple mitogen-activated protein kinase pathways
28. Activation of the NF-κB pathway by inflammatory stimuli in human neutrophils
29. Human tumor necrosis factor α gene regulation by virus and lipopolysaccharide
30. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees
31. Tumor necrosis factor is involved in the appearance of interleukin-1 receptor antagonist in endotoxemia
32. Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees
33. Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans
34. p38 mitogen-activated protein kinase activation is required for human neutrophil function triggered by TNF-α or FMLP stimulation
35. Cell volume-dependent regulation of L-selectin shedding in neutrophils: A role for p38 mitogen-activated protein kinase
36. Kinase pathways in chemoattractant-induced degranulation of neutrophils: The role of p38 mitogen-activated protein kinase activated by Src family kinases
37. L-selectin signaling of neutrophil adhesion and degranulation involves p38 mitogen-activated protein kinase
38. 2-integrin upregulation is blocked by a p38 MAP kinase inhibitor
39. Expression of the chemokine receptors CXCR1 and CXCR2 on granulocytes in human endotoxemia and tuberculosis: Involvement of the p38 mitogen-activated protein kinase pathway
40. p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis
41. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration
42. Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: Effect of timing of recombinant human IL-10 administration
43. Interleukin-10: Potential benefits and possible risks in clinical infectious diseases
44. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
45. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial: ATTRACT study group
46. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease: Crohn's disease cA2 study group